Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Pretreatment drug resistance (PDR) in patients with HIV varies by subtype, affecting antiretroviral therapy implementation and first-line treatment efficacy. In Hangzhou, 8.4% of newly diagnosed HIV ...

High prevalence of pretreatment and acquired drug resistance in children with HIV, especially in sub-Saharan Africa, was identified. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a ...

HIV drug resistance (HIVDR) can emerge with use of antiretroviral (ARV) drugs for HIV treatment and prevention. The increasing prevalence of drug-resistant HIV strains poses a serious threat to the ...

Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...

The FDA has authorized marketing of Vela Diagnostics’ test to detect HIV Type 1 drug resistance mutations. The test uses next generation sequencing technology, making it the first time the FDA has ...

Decoding the complex communication system of the deadliest brain cancer has revealed that an already approved HIV drug could ...